BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou ZG, Chen JB, Zhang RX, Ye L, Wang JC, Pan YX, Wang XH, Li WX, Zhang YJ, Xu L, Chen MS. Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients. Cancer Commun (Lond) 2020;40:355-69. [PMID: 32609436 DOI: 10.1002/cac2.12069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Busuioc C, Nutu A, Braicu C, Zanoaga O, Trif M, Berindan-neagoe I. Analysis of Differentially Expressed Genes, MMP3 and TESC, and Their Potential Value in Molecular Pathways in Colon Adenocarcinoma: A Bioinformatics Approach. BioMedInformatics 2022;2:474-491. [DOI: 10.3390/biomedinformatics2030030] [Reference Citation Analysis]
2 Li Y, Pan Y, Lin X, Hou J, Hu Z, Xu L, Zhou Z, Zhang Y, Chen M, Hu D. Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score. Front Pharmacol 2021;12:819985. [PMID: 35237150 DOI: 10.3389/fphar.2021.819985] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Zhou ZG, Chen JB, Zhang RX, Ye L, Wang JC, Pan YX, Wang XH, Li WX, Zhang YJ, Xu L, Chen MS. Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients. Cancer Commun (Lond) 2020;40:355-69. [PMID: 32609436 DOI: 10.1002/cac2.12069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]